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Abstract 
 
Background 
The etiology and risk factors associated with gastrointestinal bleeding (GIB) in 
patients with continuous-flow left ventricular assist devices (CF-LVADs) are 
currently unknown. Therefore, we sought to assess the risk factors for GIB in these 
patients. 
 
Design and Methods  
This was a retrospective, non-randomized, non-controlled study at a single center. 
Between 2012 and 2014, 65 men and 6 women (mean age = 55 ± 12 years) 
underwent CF-LVAD implantation at our institution. Overall, 23.9% of patients 
(17/71) had at least one GIB episode. Endoscopy confirmed GIB in 13/17. 
Arteriovenous malformation was the major GIB source in 8/13 (61%). There was 
no significant difference in incidence of GIB with regard to INTERMACS profile, 
blood type, or device type—HeartWare vs. HeartMateII. All our patients with GIB 
were men, most had hyperlipidemia, and most likely had ischemic cardiomyopathy 
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(65%) and peripheral vascular disease (24%). The only significant risk factor for 
GIB was chronic kidney disease (odds ratio= 3.95; 95% confidence interval of 1.21 
to 12.84; p=0.02). At the time of the first GIB, mean hemoglobin was 7.38 ± 1.06 
g/dl, international normalized ratio was 2.08 ± 0.69 IU, and mean arterial pressure 
was 75 ± 12 mmHg. Ten patients (59%) required hospital admission for treatment. 
 
Conclusion 
In our patients GIB was often a single event and often occurred within first month 
after implantation. Prevention strategies should be focused on this vulnerable 
period, especially in patients with chronic kidney disease 
Keywords:  gastrointestinal bleeding, left ventricular assist device (LVAD), heart 
failure, thromboembolic event 
 
Introduction 
 
The use of a left ventricular assist device (LVAD) either as a bridge to 
transplantation or a destination therapy has significantly improved survival for end-
stage heart failure patients.1,2 The new generation of continuous flow devices have 
favorable characteristics; they are small, durable, and are associated with fewer 
adverse events than pulsatile LVADs. Nevertheless, important comorbidities 
associated with these devices do exist, and they are partly related to bleeding 
diathesis. Bleeding complications following LVAD implant are common and 
contribute significantly to morbidity and mortality. Overall bleeding rates are in the 
range of 45% to 55% with gastrointestinal bleeding (GIB) occurring in 
approximately 25% of patients with LVADs.1,3-6 This results in hospital 
readmissions and treatment, which increases the total cost of care considerably.  
 
It has been suggested that reduced pulse pressure induced by CF-LVADs results 
in hypoperfusion of the gastrointestinal mucosa and neovascularization in friable 
vessels that are prone to bleeding.7 These gastrointestinal angiodysplastic 
conditions are found at increased rates in patients after CF-LVAD implantation.4,8 
The high incidence of bleeding has also been attributed to the development of 
acquired von Willebrand syndrome (AVWS), which is a deficiency of the high 
molecular weight von Willebrand multimers (HMWM).9,10 The shear forces on 
blood components created by continuous flow LVADs damage and inactivate 
HMWM. The complex interaction between a patient's innate hemostatic 
characteristics, anatomical predisposition for bleeding, AVWS, and anticoagulation 
therapy all contribute to the development of the bleeding complications.11 
Management of GIB requires alteration of anticoagulation and antiplatelet therapy, 
consequently complicating the already altered thrombotic profile and increasing 
the risk of thromboembolic (TE) events, including pump thrombosis.5 
 
The aim of this study was to identify the characteristics of patients who had 
undergone implantation of a CF-LVAD and had experienced nonsurgical GIB 
events. We sought to evaluate risk factors that make these patients prone to GIB 
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and determine their additional TE hazard in order to improve management of this 
complication. 
Methods 
Study Population 
This single-center retrospective study included 71 patients (65 men and 6 women) 
underwent implantation of a CF-LVAD; HeartMate II (Thoratec Corporation, 
Pleasanton, CA) (HMII) 50 patients, and HVAD (HeartWare Inc., Framingham, 
MA) in 21 patients. Pre-operative clinical characteristics were recorded for all 
patients and included INTERMACS profile, presence of coronary artery disease, 
peripheral vascular disease, diabetes, presence of a known GI disease, prior 
stroke, chronic kidney disease, atrial fibrillation, hypertension, and hyperlipidemia. 
The Institutional Review Board approved the study and all patients gave informed 
consent for participation. 
After LVAD implantation, patients were started on intravenous heparin and 
transitioned to oral anticoagulation therapy with warfarin between postoperative 
days 2 and 5. Thereafter, all patients received 81mg aspirin and warfarin to 
achieve the target INR of 2–3 IU. Additional antiplatelet therapy with 75mg 
dipyridamole 3 times per day was given in 2 of 71 patients who had developed 
device thrombosis. Platelet function was monitored by light transmittance 
aggregometry in all patients pre-operatively and during bleeding episodes. The 
pump speed setting of both devices was determined by ramp speed 
echocardiogram studies. During the first 24 hours after implantation in patients 
with the HMII, pump speed was increased under echocardiographic guidance up 
to 8800 revolutions per minute (RPM) to allow aortic valve opening with a ratio of 
1:3. In HVAD-supported patients, pump speed was increased up to 2800 RPM. 
Later, pump speed was optimized on the basis of patient symptoms, suction 
events, and echocardiographic evaluation. 
  
Outcome Assessment  
Major bleeding was defined as an episode of suspected internal bleeding resulting 
in transfusion of packed red blood cells (RBCs), hospitalization, surgical 
intervention, or death.7 In specific cases, GIB was defined by clinical evidence of 
bleeding (guaiac-positive stool, melena, hematemesis, hematochezia, or the 
presence of blood in the GI tract on endoscopic evaluation) with a decrease in 
hemoglobin (Hb)≥ 2 g/dl compared to the patient’s Hb value at the time of the last 
follow-up. Multiple bleeding events during the same hospitalization were counted 
as the same event. Patients underwent upper endoscopic examination 
(esophagogastroduodenoscopy or small-bowel enteroscopy) in the presence of 
melena and/or hematemesis and underwent colonoscopy when presenting with 
hematochezia and medically stable. Gastrointestinal bleeding was categorized as 
upper GIB, proximal to the ligament of Treitz, or lower GIB, distal to the ligament of 
Treitz. 
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Anticoagulation therapy was discontinued until active GIB stopped. The decision to 
restart anticoagulation therapy was based on clinical assessment after the 
remission of active GIB. Treatment options for bleeding vessels were endoclips 
with epinephrine injections or cauterization (argon plasma coagulation or gold 
probe cauterization). Additionally, medical gastro-protective therapy with proton 
pump inhibitors was utilized.  
We also analyzed patients on LVAD support for thromboembolic (TE) events 
(stroke, transient ischemic attack, and confirmed or suspected pump thrombus), 
hemolysis, right heart failure, respiratory failure, renal and hepatic dysfunction, and 
survival. The primary goal of this study was to analyze the frequency of GIB as 
well as the location and etiology of GIB in both LVAD groups. The frequency of TE 
events was analyzed as well. Median follow-up and LVAD support was 6 months 
(3 to 23months). 
Statistical Analysis 
Data analysis used SPSS 22.0 statistical software (SPSS, Inc., Chicago, IL), and 
values are expressed as mean ± standard deviation for normally distributed data 
or as medians with ranges for non-normally distributed continuous data. 
Categorical data are presented as percentages. Student’s t-test and the 
independent samples Mann–Whitney test for continuous variables or the chi-
square test for categorical data were used to compare data between the two 
groups. Fisher’s exact test was used when appropriate. Logistic regression 
analysis was used to identify risk factors for GIB. A p value <0.05 was considered 
statistically significant. 
Results 
Twenty-five GIB episodes were recorded in the 17/71 (23.9%) patients. Patients 
with GIB were all men, with a mean age of 59 ± 8 years. Median time to the first 
GIB episode was 21 days (range, 11 to 140 days), with 11/17 episodes occurring 
within first month after the pump implantation. Fourteen patients had a single 
episode, and 3 patients had multiple bleeding episodes (3, 4, and 4 bleeding 
episodes, respectively). The second bleeding episode occurred 20, 24 and 110 
days after the first bleeding episode, respectively. All patients with multiple GIBs 
had HMII pump.   
Preoperative data for patients with GIB and those without are shown in Table 1. In 
patients with GIB, significantly more patients had chronic kidney disease, and 
more patients had hyperlipidemia, but the latter difference did not reach 
significance. Two patients had known past medical history of GI peptic ulcers. On 
logistic regression analysis, the only risk factor significant for GIB was the 
presence of chronic kidney disease (odds ratio=3.95; 95% confidence interval of 
1.21 to 12.84; p=0.02).  
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Table 1. Baseline Patient Characteristics 
 GIB (N=17) Non-GIB (N=54) p Value 
Age (year) 59 ± 8 54 ± 13  0.145 
Men/women 17/0 48/6 0.151 
Body mass index (kg/m2) 29.1 ± 6.3 29.9 ± 7.0 0.699 
Heart disease   0.289 
Ischemic cardiomyopathy 11 (65) 27 (50)  
Idiopathic cardiomyopathy 6 (35) 27 (50)  
Diabetes mellitus 12 (71) 28 (52) 0.174 
Hypertension 14 (82) 45 (83) 0.925 
Hyperlipidemia 12 (71)  23 (43) 0.055 
Myocardial infarction 9 (53) 25 (46) 0.632 
Peripheral vascular disease 4 (24) 5 (9) 0.123 
Chronic kidney disease 11 (65) 16 (30)  0.019 
Atrial fibrillation/flutter 8 (47) 17 (32) 0.241 
Chronic obstructive pulmonary dis. 2 (12) 6 (11) 0.941 
Stroke 4 (24) 4 (7) 0.067 
GI ulcer 1 (6) 1 (2) 0.381 
LV ejection fraction (%) 19 ± 5 20 ± 7 0.343 
LV end-diastolic dimension (cm) 6.8 ± 0.8 6.5 ± 1.2 0.476 
Mean arterial pressure (mmHg) 88 ± 14  82 ± 12 0.163 
Sodium (mEq/L) 137 ± 4.0 137 ± 4.9 0.807 
Blood urea nitrogen (mg/dl) 29.8 ± 17 31.7 ± 19 0.713 
Creatinine (mg/dl) 1.83 ± 1.4 1.62 ± 0.8 0.430 
AST (IU/L) 30 (17–203) 34 (4–789) 0.558 
ALT (IU/L) 36 (20–289) 36 (8–1574) 0.848 
Total bilirubin (mg/dl) 0.8 (0.4–10.7) 1.0 (0.4–120) 0.327 
Albumin (g/dl) 2.9 ± 0.63 3.02 ± 0.55 0.631 
INR (IU) 1.2 ± 0.2 1.4 ± 0.6 0.383 
Device   0.554 
HVAD 6 (35) 15 (28)  
HMII 11 (65)  39 (72)   
BTT/DT 14/3 28/26 0.026 
Intensive care unit stay (days) 9 ± 5 16 ± 18  0.321 
Pre-implantation support    
ECMO 0 (0) 5 (9) 0.189 
IABP 3 (18) 10 (19) 0.910 
TandemHeart 2 (12) 7 (13) 0.877 
Blood type   0.805 
O 9 (53) 27 (50)  
A 5 (29) 15 (28)  
B 3 (18) 9 (17)  
AB 0 (0) 3 (5)  
INTERMACS score   0.231 
1 5 (29) 20 (37)  
2 7 (41) 13 (24)  
3 3 (18) 16 (30)  
4-7 2 (12) 5 (9)  
 
Results are presented as mean ± standard deviation, median (range), or number of 
patients (%). 
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Abbreviations: GIB, gastrointestinal bleeding; ALT, alanine amino transferase; AST, 
aspartate amino transferase; BTT, bridge-to-transplant; DT, destination therapy; ECMO, 
extracorporeal membrane oxygenation; GI, gastrointestinal; HMII, HeartMate II; HVAD, 
HeartWare; IABP, intra-aortic balloon pump; INR, international normalized ratio; LV, left 
ventricle. 
 
All patients with GIB presented with anemia — also, 8 with melena, 1 with 
hematemesis, 6 without obvious bleeding source, and 2 with only positive guaiac 
stool test. Esophagogastroduodenoscopy (EGD), small-bowel enteroscopy, and 
colonoscopy confirmed bleeding sources in 13 patients. Arteriovenous 
malformations (AVMs) were identified as the major source of bleeding in 8/13 
patients (61%). The location of the first incidence of GIB is summarized in Table 2.  
 
Table 2. Location of the First Gastrointestinal Bleeding Event after Left 
Ventricular Assist Device Implantation 
Location N 
Upper GI 9 
Mallory–Weiss tear 1 
Gastric AVM 2 
Gastric ulcer 1 
Gastric polyp 1 
Duodenal AVM 2 
Jejunal AVM 2 
Lower GI 6 
Cecal AVM 1 
Cecal ulcer 1 
Distal transverse colon ulcer 1 
Sigmoid colon diverticulosis 1 
Sigmoid colon AVM 1 
Rectal AVM 1 
 
Abbreviations : GI – gastrointestinal, AVM-arteriovenous malformations 
 
In 2 patients endoscopy confirmed bleeding from 2 sources during the same GIB 
episode. One patient had both gastric and jejunal AVM. The other patient had 
rectal AVM and sigmoid colon diverticulosis. In 1 patient, the small bowel AVM 
was identified only by on-table push enteroscopy because EGD, colonoscopy, 
nuclear medicine study, and angiograms failed to diagnose the bleeding source. 
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GI endoscopy was not performed in 2 patients—1 with melena and 1 without 
obvious bleeding source—due to hemodynamic instability. In another 2 patients, 
conclusions were made by guaiac-positive stool tests only. These 4 patients 
experienced single bleeding episodes. For the 17 patients with GIB, characteristics 
at the time of the first bleeding episode are shown in the Table 3. All patients had 
body mass index (BMI)>18.5kg/m2 at the time of the GIB. Patients with multiple 
GIBs displayed trends toward higher INR values, lower PTT values, and lower 
creatinine levels (Table 4). Only 1 patient with multiple GIB episodes was 
diagnosed with coagulopathy (factor deficiency in the common or in both intrinsic 
and extrinsic pathways), and one patient had GIB whenever his INR value 
exceeded 2IU.  
 
Table 3. Patient Characteristics at the Time of the First Gastrointestinal 
Bleeding Event 
 GIB (N=17) 
Hemoglobin (g/dl) 7.38 ± 1.06 
INR (IU) 2.08 ± 0.69 
Prothrombin time (s) 23.21 ± 5.81 
Partial thromboplastin time (s) 48.15 ± 12.5 
Platelet count 232 ± 98 
Blood urea nitrogen (mg/dl) 33 ± 15 
Creatinine (mg/dl) 2.02 ± 1.33 
Albumin (g/dl) 2.35 ± 0.49 
Mean arterial pressure (mmHg) 75 ± 12 
Discharge INR (IU) 1.65 ± 0.52 
 
Results are presented as median (range), mean ± standard deviation, or number 
(%).  
Abbreviations: N, number of patients with gastrointestinal bleeding; INR, 
international normalized ratio; RBC, red blood cells.  
 
Table 4. Characteristics of Patients with Single and Multiple GIB 
Parameter  Single GIB (N=14) Multiple GIB 
episodes (N=3)* 
p Value 
INR (IU) 1.86 ± 0.5 2.49 ± 1.33 NS 
Partial thromboplastin 
time (s) 
49 ± 11 36 ± 14 NS 
Creatinine (mg/dl) 2.4 ± 1.6 1.4 ± 0.3 NS 
Albumin (g/dl) 2.34 ± 0.5 2.23 ± 0.7 NS 
Right heart dysfunction 
(n) 
11 1 NS 
 
Abbreviations: NS, not significant; GIB, gastrointestinal bleeding; INR, international 
normalized ratio.* Average of all episodes. 
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Of the 17 patients with GIB, 7 were hemodynamically stable (MAP> 70 mmHg, 
Hb≥ 7.0 g/dl, and INR <3.5 IU) when presenting at hospital. The other 10 required 
additional medical management for hemodynamic instability while hospitalized. 
LVAD operating parameters at the time of GIB episode and at 30-day follow-up are 
shown in Table 5.  
Table 5. LVAD Operating Parameters at 30-Days after LVAD Implant and at 
the First GIB Episode  
 
 
Patients without 
GIB at 30 days 
on LVAD  
Patients with GIB 
at 30 days on 
LVAD  
Patients with GIB 
at first GIB 
episode 
p 
Value 
      
HMII 
N=39 N=11 N=11   
Pump speed 
(RPM) 
8400 (7990–
9000) 
8800 (8200–
9000) 
8400 (8000–
9000) 
0.069 
Pump flow (LPM) 5 (2.9–8.5) 4.8 (4.3–6.3) 5.5 (4.4–7.7) 0.876 
Pump power (W) 4.8 (3.9–6.8) 5 (4.3–6.9) 5.4 (4.1–7.5) 0.113 
Pulsatility index 6.2 (4–8) 5.6 (3.8–8.7) 6.1 (3.8–8.6) 0.626 
Pulsatility (y) 14 3 11 (58) 0.828 
MAP (mmHg) 78 ± 11 78 ± 10        78 ± 12 0.741 
HVAD 
N=15 N=6 N=6   
Pump speed 
(RPM) 
2500 (2400–
2800) 
2580 (2500–
2600) 
2560 (2500–
2600) 
0.467 
Pump flow (LPM) 5 (3.8–7.3) 5.5 (5.0–6.2) 4.9 (4.6–5.7) 0.387 
Pump power (W) 3.4 (2.7–4.8) 3.7 (3.0–4.0) 3.4 (3.2–3.4) 0.765 
Pulsatility index n/a n/a n/a n/a 
Pulsatility (y) 9 4 0 0.023 
MAP (mmHg) 75 ± 8 77 ± 10          70 ± 12 0.701 
 
Results are presented as median (range), mean ± standard deviation, or number. 
N, number of patients. 
n/a, not applicable. 
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Abbreviations: GIB, gastrointestinal bleeding; HMII, HeartMate II; HVAD, 
HeartWare; LPM, liters per minute; RPM, revolutions per minute; MAP, mean 
arterial pressure. 
 
Patients with multiple GIB episodes received, on average, 3.5 units of RBCs plus 2 
units of fresh frozen plasma (FFP) at the second bleeding episode and 2.5 and 2 
units of RBCs at the third and fourth bleeding episode, respectively. There were no 
platelet transfusions or cryoprecipitate transfusions. After discharge from the first 
GIB episode, the majority of patients were restarted on both aspirin and warfarin 
therapy (92%), with only 1 patient restarted on triple warfarin-aspirin-dipyridamole 
therapy. 
There were 3 TE events in our group of patients with GIB: 1 transient ischemic 
attack 345 days after device implantation, 1 stroke 53 days after device 
implantation, and 1 confirmed device thrombosis 86 days after LVAD placement. 
Two patients had thromboembolic events at 26 days and 24 days after the GIB 
event. The first patient had multiple GIB events and was receiving only aspirin at 
the time of the event. He subsequently underwent heart transplantation for device 
thrombosis (not pump replacement). In total 3 patients with GIB underwent heart 
transplantation. One patient with GIB died of multiple organ failure within 30 days 
after LVAD implantation.   
Discussion  
In summary, pump thrombosis has been and continues to remain a major adverse 
event during destination therapy. Pump thrombosis may have been initially 
underestimated. Aggressive monitoring of anticoagulation and hemolysis is the 
sine qua non of pump thrombosis prevention. We observed GIB complications in 
nearly 25% our patients supported with CF-LVADs, with no difference between the 
types of LVADs. AVMs were the most common etiology. Overall, patients with and 
without GIB had similar pre-implantation characteristics, perioperative adverse 
events, and survival rates. The majority of our patients with GIB received LVAD 
support as a bridge to transplant, and they were not statistically older than patients 
without GIB, which has been recognized as a risk factor in previous studies.12 The 
only patient characteristic that was significantly associated with GIB was the 
presence of chronic renal insufficiency. This has been linked with nonsurgical 
bleeding in different clinical settings.7,12,13 . All our patients with GIB were male, 
most had hyperlipidemia, and most likely had ischemic cardiomyopathy (65%) and 
peripheral vascular disease (24%). 
Previously, it has been shown that patients with O blood type have lower levels of 
measured von Willebrand factor and factor VIII.15 However, in our study group, the 
presence of blood type O was not associated with increased risk of bleeding. In 
88% of our patients, bleeding events occurred in the absence of supratherapeutic 
anticoagulation, with no patient having an INR> 4.7,14 No abnormality was 
observed in baseline platelet function of patients with GIB. The AVWS, LVAD 
pump speed, lack of pulsatility, and platelet aggregation have been implicated in 
the increased incidence of bleeding in CF-LVADs. In our study group, HMWMs 
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were not routinely measured, but recently published papers show that AVWS is 
found in all patients with CF-LVADs.16-18  
Treatment for GIB involves decreasing INR goals and withholding antiplatelet and 
anticoagulation medications. This places the patient at increased risk of TE events 
while on VAD support.19,20 The patient with documented pump thrombus in our 
study previously had multiple GIB events and was receiving only 81mg aspirin at 
the time of thrombosis. Patients with stroke and TIA had both anticoagulation and 
antiplatelet therapy at the time of their TE events. Our institutional policy for 
anticoagulation and antiplatelet therapy after the first GIB event is warfarin with 
81mg aspirin and a target INR of 1.5–2. If there is recurrence of GIB after the first 
event, patients will still receive warfarin to achieve a target INR of 1.5–2 but 
without any antiplatelet therapy. After a third event, patients are discharged with all 
anticoagulation and antiplatelet therapy withheld.  
For patients with multiple GIB events, testing for coagulopathy should be utilized 
as an additional diagnostic measure to determine desirable INR in that 
subpopulation of LVAD recipients. It was shown that LVAD patients have an 
increase in activated endothelial cells, which leads to expression of inflammatory 
markers that can promote coagulopathies in addition to the hypercoagulable state 
and predisposition of platelet activation due to direct contact between blood and 
the foreign material of the LVAD.3,21 Patients with multiple GIB events when 
INR>2IU helped us determine our institutional policy for anticoagulation and 
antiplatelet therapy after the bleeding event. Prior to bleeding events, our patients 
are generally prescribed warfarin with INR goals of 2–3, but therapy is often 
discontinued after patients experience GIB and is then restarted after GIB 
resolves. None of the confirmed GIB events were fatal in our study group. 
It has been hypothesized that a lower pump speed in an LVAD may result in 
higher pulse pressures and fewer GIB events.22 Conversely, higher pump speed 
may result in decreased capillary pressure and ischemia in the GI mucosa in 
addition to AVWS.21 Also, a lower LVAD pump speed may cause less dispersal of 
heat and increased propensity for clot formation.23 In theory, the HVAD contact-
free design and lower pump speed should provide cardiac support with lower 
levels of sheer stress, preserving HMWM.16,17 Although the HVAD pump speed is 
low, it still reaches a sufficient threshold to induce von Willebrand factor unfolding 
and loss of HMWM, with higher speed corresponding to greater loss of 
HMWM.16,17 The association between severe right ventricular (RV) dysfunction and 
increased bleeding risk could also be related to a more advanced stage of heart 
failure.7 Patients with severe RV dysfunction can present clinically with low LVAD 
flows and low pulsatility index, which could additionally explain the association 
between RV dysfunction and bleeding risk.7 Similarly, severe RV dysfunction and 
portal hypertension are associated with malnutrition, and abnormal liver function 
increases risk of bleeding.24,25 It should be noted that the sample size in this study 
may have limited the study’s ability to detect statistically significant differences in 
some of the variables compared. Similarly, this study consisted of patients 
receiving LVAD support mainly as bridge-to-transplant therapy, which may have 
selected for certain patient characteristics. Also, von Willebrand factor multimers 
were not routinely measured. Future prospective multicenter trials are still needed 
to further assess the mechanisms of GIB and TE events. 
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As the number of patients receiving LVAD support grows worldwide, it is expected 
that adverse bleeding events will increase, with a significant increase of cost for 
patient hospitalization and management.1,7 For these patients, standard upper 
endoscopy and colonoscopy, offered as diagnostic and therapeutic medical 
procedures, as well as video capsule or surgical push enteroscopy can be 
performed in an outpatient setting with gastrointestinal protective therapy (proton 
pump inhibitors), interruption of warfarin therapy, and iron supplements. Afterward, 
a new regimen for anticoagulation therapy can be designed for the patient. 
Patients requiring blood transfusion, FFP, cryoprecipitate, or Vitamin K antagonist 
therapy would be managed in an outpatient setting as well. Management of these 
patients with such a plan requires a team-based approach and good coordination 
among cardiologists, gastroenterologists, and hematologists in an outpatient 
setting.  
This was a retrospective, non-randomized, non-controlled study at a single center. 
The limited sample size and patient characteristics make comparison to other 
reports difficult. Although the percentage of patients with GIB was comparable to 
other studies, the median time to the first GIB event in our study was only 21 
days—considerably earlier than other reports.20,26 However, other studies have 
shown that the time to first GIB is as soon as 8 days27 and as long as 383 days28, 
and the range in our study was 11 to 140 days.  Although we did not investigate 
this phenomenon, we suspect that some factors that may influence the time to first 
GIB are severity of illness, renal disease, age, gender, anticoagulation and 
antiplatelet therapy, prior GI pathology and degree of AVWS. More studies are 
needed to better understand both the time of first GIB and the time to recurrence 
of GIB. 
In conclusion, GIB occurs mainly as a single event that is widely variable in timing, 
but may present within the first month after surgery. Therefore, prevention 
strategies should be focused on this vulnerable post-implantation period, 
especially in patients with chronic kidney disease.  
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